Controlling giardiosis
View Patent ↗The present invention relates to the use of nifurtimox for the treatment of giardiosis, in particular in dogs and cats.
1. A pharmaceutical formulation comprising nifurtimox and an anthelmintic comprising a cyclooctadepsipeptide.
2. A method of treating a disease caused by a Giardia species in an animal comprising administering to the animal in need thereof a pharmaceutical formulation comprising nifurtimox.
3. The method of claim 2 , wherein the Giardia species is Giardia lamblia.
4. The method of claim 2 , wherein the pharmaceutical formulation further comprises an anthelmintic.
5. The method of claim 4 , wherein the anthelmintic comprises a cyclooctadepsipeptide.
6. The method of claim 5 , wherein the cyclooctadepsipeptide comprises a compound selected from the group consisting of PF1022, PF1022A, PF1022-221, salts thereof, and solvates thereof.
7. The method of claim 2 , wherein the pharmaceutical formulation comprising nifurtimox is administered orally to the animal.
8. The method of claim 7 , wherein the pharmaceutical formulation comprising nifurtimox is a tablet.
9. The method of claim 7 , wherein the pharmaceutical formulation comprising nifurtimox is administered to the animal by metering into the animal's feed or drinking water.
10. The method of claim 2 , further comprising applying a disinfectant to a location where infectious feces is excreted by the animal during treatment.
11. A method of treating a disease caused by a Giardia species and a nematode infection in an animal comprising administering to the animal in need thereof a pharmaceutical composition comprising nifurtimox and an anthelmintic.
12. The method of claim 11 , wherein the Giardia species is Giardia lamblia.
13. The method of claim 11 , wherein the anthelmintic comprises a cyclooctadepsipeptide.
14. The method of claim 13 , wherein the cyclooctadepsipeptide comprises a compound selected from the group consisting of PF1022, PF1022A, PF1022-221, salts thereof, and solvates thereof.
15. The method of claim 11 , wherein the pharmaceutical formulation comprising nifurtimox is administered orally to the animal.
16. The method of claim 15 , wherein the pharmaceutical formulation comprising nifurtimox is a tablet.
17. The method of claim 11 , wherein the pharmaceutical formulation comprising nifurtimox is administered to the animal by metering into the animal's feed or drinking water.
18. The method of claim 11 , further comprising applying a disinfectant to a location where infectious feces is excreted by the animal during treatment.
19. The pharmaceutical formulation of claim 1 , wherein the cyclooctadepsipeptide comprises a compound selected from the group consisting of PF1022, PF1022A, PF1022-221, salts thereof, and solvates thereof.
20. The pharmaceutical formulation of claim 1 , wherein the cyclooctadepsipeptide is emodepside, salt thereof, or solvate thereof.